Xyzal M Suspension is a combination pharmaceutical formulation containing Levocetirizine dihydrochloride 2.5 mg and Montelukast sodium 4 mg per 5 ml of oral suspension. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 histamine receptors, effectively reducing symptoms of allergic rhinitis such as sneezing, nasal congestion, rhinorrhea, and itching. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene receptor, thereby preventing bronchoconstriction, inflammation, and mucus secretion associated with asthma and allergic rhinitis. The synergistic action of these active ingredients provides comprehensive relief from allergic conditions by targeting both histaminergic and leukotriene-mediated pathways. Xyzal M Suspension is indicated for the management of allergic rhinitis, chronic urticaria, and mild to moderate asthma in pediatric patients requiring dual therapy. The suspension form facilitates ease of administration and accurate dosing in children. It is generally well tolerated; however, adverse effects may include headache, drowsiness, abdominal pain, and gastrointestinal disturbances. Use with caution in patients with hepatic or renal impairment, and consult healthcare professionals before initiating therapy in patients with a history of neuropsychiatric events. Xyzal M Suspension should be used as directed to optimize therapeutic outcomes and improve patient quality of life.